Efficacy of denosumab therapy after alendronate treatment for a 66-year-old woman with Camurati–Engelmann disease and osteoporosis: a case report

Abstract

Camurati–Engelmann disease (CED) is characterized by hyperostois of multiple long bones. Although several treatments for CED complicated with osteoporosis have been described, it remains controversial whether such therapy is suitable for osteoporotic CED patients. We retrospectively enrolled a 66-year-old female patient with osteoporosis in CED who underwent denosumab therapy for 14 months. Denosumab was commenced after 3 years of alendronate treatment. Fourteen months later, lumbar and total hip bone mineral density showed gains of 5.9% and 6.4%, respectively. Bone turnover markers were also improved during follow-up. No fractures or other complications were recorded during the observational period. This is the first study describing denosumab treatment for an osteoporotic CED patient. Our findings indicate that denosumab is an effective therapy option for osteoporosis in CED.

Keywords:

• Bone mineral density
• denosumab
• Camurati–Engelmann disease
• osteoporosis
• alendronate

Conflict of interest

None.